Morgan Stanley analyst Erin Wright raised the firm’s CVS Health (CVS) to $89 from $82 and keeps an Overweight rating on the shares. Last week’s Stars results were “encouraging” for the sector and Managed Care Organization sentiment has “improved slightly,” but there is “still a lot to prove” as the focus turns to utilization and early reads on 2026, the analyst tells investors in a Q3 earnings preview for the group.
-
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Read More on CVS:
Disclaimer & DisclosureReport an Issue
Source: finance.yahoo.com
